Key result
Tideglusib preserves cardiac function and suppresses adrenergic ventricular arrhythmias in arrhythmogenic cardiomyopathy models.
Why the study?
Does Tideglusib improve cardiac function and reduce ventricular arrhythmia in murine models of arrhythmogenic cardiomyopathy?
Does Tideglusib improve cardiac function and reduce ventricular arrhythmia in murine models of arrhythmogenic cardiomyopathy?
Tideglusib shows preclinical efficacy in preventing and reversing cardiac dysfunction and reducing ventricular arrhythmias in murine models of arrhythmogenic cardiomyopathy.
Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease, and current pharmacological therapies are directed toward the management of electrical manifestations. To date, none address the underlying pathophysiology of this progressive condition. We evaluated the therapeutic efficacy of Tideglusib (TD) in Ank2 cardio-selective-knockout and homozygous desmoglein-2 mutant ACM mouse models. TD was able to prevent and reverse the reduced cardiac function in treated mice. Moreover, TD-treated adult mice displayed a reduction in ventricular arrhythmia following adrenergic stimulation. We provide compelling preclinical data for TD as a potential therapy for patients with ACM.
No takes yet. Share an insight, caveat, or question.
Malhotra et al. (2025) studied Arrhythmogenic cardiomyopathy (ACM). Tideglusib (TD) was evaluated on Cardiac function and ventricular arrhythmia following adrenergic stimulation. Tideglusib prevented and reversed reduced cardiac function and reduced ventricular arrhythmia following adrenergic stimulation in murine models of arrhythmogenic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: